RTTNews) – AstraZeneca PLC (AZN.L, AZN) and MSD’s Lynparza in combination with abiraterone and prednisone or prednisolone has been recommended for marketing authorisation in the European Union for the treatment of adult patients with metastatic castration-resistant prostate canc…
Read More
About The Author
